These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30362288)

  • 61. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
    Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
    Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
    J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease.
    Singal M; Kouides PA
    Drugs Today (Barc); 2016 Dec; 52(12):653-664. PubMed ID: 28276537
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
    Federici AB; Santoro RC; Santoro C; Pieri L; Santi RM; Barillari G; Borchiellini A; Tosetto A; Zanon E; De Cristofaro R; Mairal E; Mir R
    Clin Appl Thromb Hemost; 2024; 30():10760296241264541. PubMed ID: 39033425
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of a VWF/FVIII concentrate (wilate
    Srivastava A; Serban M; Werner S; Schwartz BA; Kessler CM;
    Haemophilia; 2017 Mar; 23(2):264-272. PubMed ID: 28026130
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Perioperative management of patients with von Willebrand disease.
    O'Donnell JS; Lavin M
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):604-609. PubMed ID: 31808837
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
    Castaman G; Coppola A; Zanon E; Boeri E; Musso M; Siragusa S; Federici AB; Mancuso G; Barillari G; Biasoli C; Feola G; Franchini M; Moratelli S; Gamba G; Schinco P; Valdrè L; Dragani A; Mazzucconi G; Tagliaferri A; Morfini M
    Haemophilia; 2013 Jan; 19(1):82-8. PubMed ID: 22957493
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease.
    Rugeri L; Thomas W; Schirner K; Heyder L; Auerswald G
    Thromb Haemost; 2024 Sep; 124(9):828-841. PubMed ID: 38272065
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
    Miesbach W; Krekeler S; Wolf Z; Seifried E
    Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report.
    Brown R
    Blood Coagul Fibrinolysis; 2017 Oct; 28(7):570-575. PubMed ID: 28379876
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin
    Gouider E; Klukowska A; Maes P; Platokouki H; Pujol S; Henriet C; Bridey F; Goudemand J
    Blood Transfus; 2023 Jan; 21(1):83-92. PubMed ID: 35543677
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Development of a plasma- and albumin-free recombinant von Willebrand factor.
    Turecek PL; Mitterer A; Matthiessen HP; Gritsch H; Varadi K; Siekmann J; Schnecker K; Plaimauer B; Kaliwoda M; Purtscher M; Woehrer W; Mundt W; Muchitsch EM; Suiter T; Ewenstein B; Ehrlich HJ; Schwarz HP
    Hamostaseologie; 2009 Oct; 29 Suppl 1():S32-8. PubMed ID: 19763356
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
    J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods.
    Goudemand J; Scharrer I; Berntorp E; Lee CA; Borel-Derlon A; Stieltjes N; Caron C; Scherrmann JM; Bridey F; Tellier Z; Federici AB; Mannucci PM
    J Thromb Haemost; 2005 Oct; 3(10):2219-27. PubMed ID: 16194199
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study.
    Goudemand J; Bridey F; Claeyssens S; Itzhar-Baïkian N; Harroche A; Desprez D; Négrier C; Chamouni P; Chambost H; Henriet C; Susen S; Borel-Derlon A
    J Thromb Haemost; 2020 Aug; 18(8):1922-1933. PubMed ID: 32445594
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of recombinant versus plasma-derived von Willebrand factor on prolonged PFA closure times in ECMO patients with acquired von Willebrand syndrome - an observational study.
    Büchsel M; Geisen U; Beckenkamp C; Wengenmayer T; Zieger B; Westermann D; Siegel PM
    Thromb J; 2023 Jan; 21(1):4. PubMed ID: 36627675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.